On April 4, a study that looked to evaluate the impact of mitral regurgitation (MR) on outcomes after transcatheter aortic valve replacement (TAVR) and the impact of TAVR on MR was published in the Journal of the American College of Cardiology (JACC).
The study, “Transcatheter Aortic Valve Replacement: Outcomes of Patients With Moderate or Severe Mitral Regurgitation,” evaluated patients from two Canadian centers with mild or less, moderate and severe MR after TAVR.
Study authors said if left untreated, patients with severe aortic stenosis and concomitant moderate or severe MR have a very poor prognosis. TAVR procedural mortality is increased in patients with advanced MR. Nevertheless, these findings demonstrate late functional benefit in survivors and are consistent with, but do not prove, a possible late survival benefit, the authors said. MR was reduced in more than half of the patients' studies after one year. Various clinical factors may assist in identifying which patients may benefit from isolated aortic valve replacement. The authors concluded TAVR may be a reasonable strategy in carefully selected patients with combined aortic and mitral valve disease.
Read the Journal Scan here. For more TAVR news and updates and links to additional clinical documents, visit CardioSource.org/TVT.